A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Death, Death, Sudden, Infant Death, Neurobehavioral Manifestations, Neurologic Manifestations, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Sudden Infant Death, X-linked disease, connective tissue disorder, cutaneous mucinosis, hereditary disease, inborn carbohydrate metabolic disorder, inborn errors of metabolism, inherited neurodegenerative disorder, intellectual disability, lysosomal storage disease, metabolic disease, mucopolysaccharidosis, mucopolysaccharidosis type 2, nervous system disorder	Active, not recruiting	Phase 1 / Phase 2	2025-08-07		NCT04251026

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Denali Therapeutics Inc.	9

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Ann & Robert H. Lurie Children's Hospital of Chicago	Chicago	United States	144
Erasmus Medical Center	Rotterdam	Netherlands	27
McGill University Health Centre - Royal Victoria Hospital	Montreal	Canada	2
St Mary's Hospital, Manchester Academic Health Science Centre	Manchester	United Kingdom	1
UCSF Benioff Children's Hospital	Oakland	United States	10
UNC Children's Research Institute	Chapel Hill	United States	2
UPMC \| Children's Hospital of Pittsburgh	Pittsburgh	United States	1